Search Result

Results for "

LRRK2 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LRRK2 (31) AMPK (1) Apoptosis (1) Aurora Kinase (1) Autophagy (1) ERK (2) GSK-3 (1) IKK (2) JAK (2) Mitophagy (1) MNK (1) Src (1) Syk (1) VEGFR (1)
By Research Areas:	Cancer (5) Inflammation/Immunology (5) Neurological Disease (28)

Targets Recommended: LRRK2

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111493

LRRK2 inhibitor 1

LRRK2 Neurological Disease

LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC₅₀ of 6.8.

LRRK2 inhibitor 1	LRRK2	Neurological Disease
LRRK2 inhibitor 1 is a potent, selective and oral *LRRK2* inhibitor with an pIC₅₀ of 6.8.

HY-10875

LRRK2-IN-1 5+ Cited Publications	LRRK2 Apoptosis	Neurological Disease Cancer
LRRK2-IN-1 is a potent and selective LRRK2* inhibitor* with IC₅₀ of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.

HY-153058

LRRK2-IN-8	LRRK2 JAK AMPK	Neurological Disease Cancer
LRRK2-IN-8 is a *LRRK2* inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC₅₀s lower than 10 nM, and inhibits TYK2 and NUAK1 with IC₅₀s of 10-100 nM .

HY-151441

LRRK2-IN-5	LRRK2	Neurological Disease
LRRK2-IN-5 (compound 25) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC₅₀ values of 1.2 and 16 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-5 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-5 can cross the blood-brain barrier .

HY-151444

LRRK2-IN-6	LRRK2	Neurological Disease
LRRK2-IN-6 (compound 22) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC₅₀ values of 4.6 and 49 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-6 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-6 can cross the blood-brain barrier .

HY-152107A

(R,R)-LRRK2-IN-7	LRRK2	Neurological Disease
(R,R)-LRRK2-IN-7 is the isomer of LRRK2-IN-7 (HY-152107). LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes.

HY-156429

MK-1468

LRRK2 Neurological Disease

MK-1468 is a high selective and brain-penetrant inhibitor of LRRK2 with an IC₅₀ of 0.8 nM. MK-1468 can be used in study Parkinson’s disease .

MK-1468	LRRK2	Neurological Disease
MK-1468 is a high selective and brain-penetrant inhibitor of *LRRK2* with an IC₅₀ of 0.8 nM. MK-1468 can be used in study Parkinson’s disease .

HY-145317

LRRK2-IN-2	LRRK2	Neurological Disease
LRRK2-IN-2 (compoubd 22) is a potent, selective, orally active and brain-penetrant inhibitor *LRRK2, with IC₅₀* of <0.6 nM. LRRK2-IN-2 can be used for the research of Parkinson's disease .

HY-145318

LRRK2-IN-3	LRRK2	Neurological Disease
LRRK2-IN-3 (compoubd 24) is a potent, selective, orally active and brain-penetrant inhibitor *LRRK2, with IC₅₀* of 2.6 nM in human PBMCs. LRRK2-IN-3 can be used for the research of Parkinson's disease .

HY-152107

LRRK2-IN-7	LRRK2	Neurological Disease
LRRK2-IN-7 is a potent, selective, and CNS-penetrant *LRRK2* kinase inhibitor with an IC₅₀ of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes .

HY-156167

LRRK2-IN-10	LRRK2	Neurological Disease
LRRK2-IN-10 (compound 34) is a potent, mutation-selective, and brain penetrant *G2019S-LRRK2* kinase** inhibitor with IC₅₀s of 11 nM and 5.2 nM for G2019S-LRRK2 pS935 and G2019S-LRRK2 pS1292, respectively. LRRK2-IN-10 has the potential for Parkinson's disease research .

HY-16936

JH-II-127
JH-II-127 is an orally active, highly potent, selective and brain-permeable *LRRK2* inhibitor, with IC₅₀s of 6, 2 and 48 nM for wild-type *LRRK2* and *LRRK2-G2019S* and mutant *LRRK2-A2016T. JH-II-127 inhibits* Ser935 phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome .

HY-B0792

CZC-54252	LRRK2	Neurological Disease
CZC-54252 is a potent and selective *LRRK2* inhibitor with IC₅₀s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC-54252 attenuates G2019S LRRK2-induced human neuronal injury with an EC₅₀ of ~1 nM. CZC-54252 has a neuroprotective activity .

HY-B0792A

CZC-54252 hydrochloride	LRRK2	Neurological Disease
CZC-54252 hydrochloride is a potent and selective *LRRK2* inhibitor with IC₅₀s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC₅₀ of ~1 nM.CZC-54252 hydrochloride has a neuroprotective activity .

HY-13237

GSK2578215A 2 Publications Verification	LRRK2 Autophagy Mitophagy	Neurological Disease Cancer
GSK2578215A is a potent and highly selective *LRRK2* inhibitor, which exhibits IC₅₀s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.

HY-13488

HG-10-102-01 1 Publications Verification	LRRK2 MNK	Neurological Disease
HG-10-102-01 is a highly potent, selective, and brain-penetrable *LRRK2* inhibitor, with IC₅₀ values of 20.3 and 3.2 nM against wild-type LRRK2 and *LRRK2[G2019S], respectively. HG-10-102-01 also inhibits* MNK2 and MLK1, with IC₅₀ values of 0.6 and 2.1 μM. HG-10-102-01 can be used for Parkinson's disease (PD) research .

HY-15800A

CZC-25146	LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 is a potent and orally active *LRRK2* inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases .

HY-15800

CZC-25146 hydrochloride	LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 hydrochloride is a potent *LRRK2* inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases .

HY-112855

PF-06454589	LRRK2	Neurological Disease
PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC₅₀ values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research .

HY-18163

GNE-7915

5+ Cited Publications

LRRK2 Neurological Disease

GNE-7915 is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC₅₀ of 9 nM.
HY-18163A

GNE-7915 tosylate

5+ Cited Publications

LRRK2 Neurological Disease

GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC₅₀ of 9 nM.

GNE-7915 5+ Cited Publications	LRRK2	Neurological Disease
GNE-7915 is a potent, selective and brain-penetrant inhibitor of *LRRK2* with an IC₅₀ of 9 nM.

GNE-7915 tosylate 5+ Cited Publications	LRRK2	Neurological Disease
GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of *LRRK2* with an IC₅₀ of 9 nM.

HY-12282

GNE-9605	LRRK2	Neurological Disease
GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC₅₀ value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .

HY-12477

PF-06447475

3 Publications Verification

LRRK2 Neurological Disease

PF-06447475 is a highly potent, selective and brain penetrant LRRK2 inhibitor with an IC₅₀ of 3 nM.
HY-134562

PF-06371900

LRRK2 Neurological Disease

PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor .
HY-142647

EB-42486

LRRK2 Neurological Disease

EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC₅₀ < 0.2 nM).
HY-14403

ERK5-IN-1

ERK Cancer

ERK5-IN-1 is a potent ERK5 inhibitor with an IC₅₀ of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC₅₀ of 26 nM.

PF-06447475 3 Publications Verification	LRRK2	Neurological Disease
PF-06447475 is a highly potent, selective and brain penetrant *LRRK2* inhibitor with an IC₅₀ of 3 nM.

PF-06371900	LRRK2	Neurological Disease
PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor .

EB-42486	LRRK2	Neurological Disease
EB-42486 is a novel, potent, and highly selective *G2019S-LRRK2* inhibitor (IC₅₀ < 0.2 nM).

ERK5-IN-1	ERK	Cancer
ERK5-IN-1 is a potent ERK5 inhibitor with an IC₅₀ of 87±7 nM. ERK5-IN-1 also inhibits *LRRK2*[G2019S] with an IC₅₀ of 26 nM.

HY-15796

GNE0877 2 Publications Verification	LRRK2	Neurological Disease
GNE0877 is a highly selective, orally active and brain-penetrant *LRRK2* inhibitor with an IC₅₀ of 3 nM and a K_i of 0.7 nM. GNE0877 can be used for the research of neuroscience .

HY-100411

MLi-2 4 Publications Verification	LRRK2	Neurological Disease
MLi-2 is an orally active and highly selective *LRRK2* inhibitor with an IC₅₀ of 0.76 nM. MLi-2 has the potential for Parkinson’s disease .

HY-108886

JWG-071 1 Publications Verification	ERK	Cancer
JWG-071 is the kinase-selective chemical probe for ERK5. JWG-071 inhibits ERK5 and LRRK2 with IC₅₀ values of 88nM and 109 nM, respectively .

HY-120085

PFE-360 2 Publications Verification PF-06685360	LRRK2	Neurological Disease
PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC₅₀ of 2.3 nM in vivo .

HY-13687

IKK 16 Maximum Cited Publications 16 Publications Verification	IKK LRRK2	Inflammation/Immunology
IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC₅₀s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC₅₀ of 50 nM.

HY-148353

PF-06455943	LRRK2	Neurological Disease
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC₅₀ value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .

HY-13687A

IKK 16 hydrochloride Maximum Cited Publications 16 Publications Verification	IKK LRRK2	Inflammation/Immunology
IKK 16 hydrochloride is a selective IκB kinase (IKK) inhibitor for IKK2, IKK complex and IKK1 with IC₅₀s of 40 nM, 70 nM and 200 nM, respectively . IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC₅₀ of 50 nM .

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, *LRRK2, GSK3β, JAK2, VEGFR2, Aurora B* and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

LRRK2 Inhibitor

Inhibitors & Agonists